Spontaneous EEG recordings (right) from a 28-month-old child with Dup15q syndrome show diffuse beta frequency oscillations that represent an electrophysiological biomarker of the disorder. Credit: Kleinhern.

Takeda Pharmaceutical Company, in collaboration with Ovid Therapeutics, is set to begin three clinical trials of TAK-935/OV935 to treat a number of paediatric patients.

The proposed trials are titled ARCADE, ELEKTRA and ENDYMION.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

ARCADE is a Phase ll, multicentre, open-label pilot trial that intends to investigate TAK-935/OV935 for the treatment of patients with either CDKL5 deficiency disorder (CDD) or Duplication 15q (Dup15q) syndrome.

The trial is expected to enrol around 30 patients aged two to 17 years, with around 15 children with each syndrome.

Its primary objective is to evaluate the frequency of motor seizures in patients treated with TAK-935/OV935, while the trial’s key secondary objectives include safety, tolerability and pharmacokinetic (PK) assessments.

ELEKTRA is a Phase ll, multicentre, randomised, double-blind, placebo-controlled trial designed to examine the efficacy, safety and tolerability of TAK-935/OV935 in patients with Dravet syndrome or Lennox-Gastaut syndrome.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Nearly 125 patients aged two to 17 years are expected to be included in this trial.

“The trial’s primary objective is to evaluate the frequency of seizures in patients treated with TAK-935/OV935 compared to placebo.”

The trial’s primary objective is to evaluate the frequency of seizures in patients treated with TAK-935/OV935 compared to placebo, while its key secondary objectives are safety, tolerability and PK assessments.

The proposed ENDYMION is a multicentre, open-label, long-term extension study of TAK-935/OV935 to treat patients with developmental and epileptic encephalopathies (DEEs) who participated in a previous TAK-935/OV935 clinical trial.

The primary objective of the study is to analyse the long-term safety and tolerability of TAK-935/OV935 over two years of treatment in patients with rare epilepsies.

The trial’s secondary endpoint will evaluate the effect of TAK-935/OV935 on seizure frequency over two years.

According to Takeda, the three new trials will join a clinical development programme that includes a fully enrolled Phase lb/lla trial of adults with DEE.

The trials will also investigate the potential of TAK-935/OV935 to modulate the N-Methyl-D-Aspartate (NMDA) signalling receptor, which has been implicated in various neurologic disorders.